{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.6","upperLimit":"97.8","value":"89.7"},{"groupId":"OG001","lowerLimit":"32.9","upperLimit":"81.6","value":"58.8"},{"groupId":"OG002","lowerLimit":"89.9","upperLimit":"99.3","value":"96.4"},{"groupId":"OG003","lowerLimit":"89.6","upperLimit":"100.0","value":"98.0"},{"groupId":"OG004","lowerLimit":"79.8","upperLimit":"99.3","value":"93.9"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.6","upperLimit":"97.8","value":"89.7"},{"groupId":"OG001","lowerLimit":"32.9","upperLimit":"81.6","value":"58.8"},{"groupId":"OG002","lowerLimit":"89.9","upperLimit":"99.3","value":"96.4"},{"groupId":"OG003","lowerLimit":"89.6","upperLimit":"100.0","value":"98.0"},{"groupId":"OG004","lowerLimit":"79.8","upperLimit":"99.3","value":"93.9"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants with MCyR is reported by arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"24 months","title":"Major Cytogenetic Response (MCyR) Rate up to 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}